Chardan Capital maintains Buy rating on Adagene, $9 price target
Chardan Capital kept a Buy rating and $9 price target on Adagene, implying 248.8% upside from the Oct 27 close. The firm cited Adagene's strong immunotherapy pipeline, including ADG126 in clinical trials, and its advanced antibody design technologies.
How this was made

The 30-second read
Why it matters
The analyst's price target suggests significant upside but hinges on trial success.
Market read
Analyst rating may drive short-term buying pressure in ADGE.
What to watch
Potential regulatory or trial setbacks could limit upside.
Background
Adagene is a clinical-stage biotech developing immunotherapy candidates, with ADG126 in early-phase trials.
Market effects
Highlights continued optimism in biotech small-caps and may influence peer valuations.
Limited to US biotech investors; no broader market effect.
Minimal global impact beyond niche biotech community.
Counterpoint
The high target may be overly optimistic given early-stage trial status.
Key entities
- companyAdagene
Biotech firm developing immunotherapy candidates.
- analystChardan Capital
Equity research firm issuing the rating.
